The development of molecularly targeted anticancer therapies: An Eli Lilly and Company perspective

Clinical Advances in Hematology and Oncology

Volumn 3, Issue 3, 2005, Pages

  Perry III, William L ^a   Weitzman, Aaron ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; CATHARANTHUS ROSEUS EXTRACT; CHLORMETHINE; GEFITINIB; GEMCITABINE; IMATINIB; K RAS PROTEIN; MUSTARD GAS; PEMETREXED; PLANT EXTRACT; RITUXIMAB; TRASTUZUMAB; UNCLASSIFIED DRUG; VINBLASTINE SULFATE; VINCRISTINE SULFATE;

ACUTE LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER GENETICS; CANCER RESEARCH; CATHARANTHUS ROSEUS; CLINICAL TRIAL; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDUSTRY; DRUG MARKETING; DRUG MECHANISM; DRUG RESEARCH; DRUG TARGETING; GENE EXPRESSION PROFILING; GENE TARGETING; HUMAN; LUNG NON SMALL CELL CANCER; LYMPHOSARCOMA; MAXIMUM TOLERATED DOSE; NONHUMAN; PANCREAS CANCER; PLEURA MESOTHELIOMA; SKIN CANCER; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG EVALUATION; DRUG INDUSTRY; DRUG SCREENING ASSAYS, ANTITUMOR; FORECASTING; HUMANS; MICE; NEOPLASM PROTEINS; NEOPLASMS;

EID: 25844462373     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Papac Rj. Origins of cancer therapy. Yale J Biol Med. 2001;74:391-398.
2. Berenblum, I. The modifying influence of dichloroethyl sulfide on the induction of tumours in mice by tar. J Pathol Bacteriol. 1929;32:425-434.
3. Adair FE, Bagg HJ. Experimental and clinical studies on the treatment of cancer by dichloroethylsulfide (mustard gas). Ann Surg. 1931;93:190-199.
4. Goodman LS, Wintrobe MM, Dameshek W, Goodman JJ, Gilman A. Nitrogen mustard therapy. Use of methyl-bis(beta-chloroethyl)amine hydrochloride and tris(beta-chloroethyl)amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders. JAMA. 1946;132:126-132.
5. Gilman A, Philips FS. The biological actions and therapeutic applications of beta-chloroethyl amines and sulfides. Science. 1946; 103:409-415.
6. Gilman A. The initial clinical trial of nitrogen mustard. Am J Surg. 1963;105:574-578.
7. Johnson IS, Cullinan GJ, Boder GB, Grindey CB, Laguzza BC. Structural modifications of the vinca alkaloids. Cancer Treat Rev. 1987; 14:407-410.
8. Gura T. Systems for identifying new drugs are often faulty. Science. 1997;278:1041-1042.
9. Jonkers J, Berns A. Conditional mouse models of sporadic cancer. Nat Rev Cancer. 2002;2:251-265.
10. Nicholson JK, Wilson ID. Opinion: understanding "global" systems biology: metabonomics and the continuum of metabolism. Nat Rev Drug Discov. 2003;2:668-676.
11. Fernie AR, Trethewey RN, Krotzky AJ, Willmitzer L. Metabolite profiling: from diagnostics to systems biology. Nat Rev Mol Cell Biol. 2004;5:763-769.
12. Sansal I, Sellers WR. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol. 2004; 22:2954-2963.
13. Johnson L, Mercer K, Greenbaum D, et al. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature. 2001;410:1111-1116.
14. Dean NM. Functional genomics and target validation approaches using anti-sense oligonucleotide technology. Curr Opin Biotechnol. 2001;12:622-625.
15. Lavery KS, King TH. Antisense and RNAi: powerful tools in drug target discovery and validation. Curr Opin Drug Discov Devel. 2003;6:561-569.
16. Jones SW, Souza PM, Lindsay MA. siRNA for gene silencing: a route to drug target discovery. Curr Opin Pharmacol. 2004;4:522-527.
17. Siegel PM, Shu W, Cardiff RD, Muller WJ, Massague J. Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. Proc Natl Acad Sci U S A. 2003;100:8430-8435.
18. Hiesberger T, Bai Y, Shao X, et al. Mutation of hepatocyte nuclear factor-1beta inhibits Pkhd1 gene expression and produces renal cysts in mice. J Clin Invest. 2004; 113:814-825.
19. Gelmon KA, Eisenhauer EA, Harris AL, Ratain MJ, Workman P. Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development? J Natl Cancer Inst. 1999;91:1281-1287.
20. Marsom S, Wittes R. Clinical development of anticancer agents - a National Cancer Institute perspective. Cancer Treat Rep. 1984;68:77-85.
21. Schilsky RL. Endpoints in cancer clinical trials and the drug approval process. Clin Cancer Res. 2002;8:935-938.
22. Korn EL, Arbuck SG, Pluda JM, Simon R, Kaplan RS, Christian MC. Clinical trial designs for cytostatic agents: are new approaches needed? J Clin Oncol. 2001;19:265-272.
23. Schirner M, Menrad A, Stephens A, Frenzel T, Hauff P, Licha K. Molecular imaging of tumor angiogenesis. Ann NY Acad Sci. 2004;1014:67-75.
24. Saijo N, Tamura T, Nishio K. Strategy for the development of novel anticancer drugs. Cancer Chemotber Pharmacol. 2003;52 (Suppl 1):S97-101.
25. Rosner GL, Stadler W, Ratain MJ. Randomized discontinuation design: application to cytostatic antineoplastic agents. J Clin OncoL 2002;20:4478-4484.
26. Gardner SN, Fernandes M. Cytostatic anticancer drug development. J Exp Ther Oncol. 2004;4:9-18.
27. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA. 2003;290:2149-2158.
28. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol. 2003;21:2237-2246.
29. Lynch Tj, Bell DW, Sordella. R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129-2139.
30. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304:1497-1500.
31. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A. 2004;101:13306-13311.
32. Couzin J. Pharmacogenomics. Cancer sharpshooters rely on DNA tests for a better aim. Science. 2004;305:1222-1223.